Furthermore, well-designed randomized controlled trials could importantly inform whether attenuating the levels of PTH intake and/or impeding platelet aggregation and procoagulant function by Vitamin D and antithrombotic agents, respectively, will decrease HF risk or mitigate its progression. The gene discussed is PTH; the disease is hydrops fetalis.